CoChat

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Ko, Tun Kiat, Javed, Asif, Lee, Kian Leong, Pathiraja, Thushangi N., Liu, Xingliang, Malik, Simeen, Soh, Sheila Xinxuan, Heng, Xiu Ting, Takahashi, Naoto, Tan, Joanna H. J., Bhatia, Ravi, Khng, Alexis J., Chng, Wee-Joo, Sia, Yee Yen, Fruman, David A., Ng, King Pan, Chan, Zhu En, Xie, Kim Jiajing, Hoi, Qiangze, Chan, Cheryl Xueli, Teo, Audrey S. M., Velazquez Camacho, Oscar, Meah, Wee Yang, Khor, Chiea Chuen, Ong, Chin Thing J., Soon, Wei Jia W., Tan, Patrick, Ng, Pauline C., Chuah, Charles, Hillmer, Axel M., Ong, S. Tiong · 2020 · Blood
Cited by 72

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterations that confer stemness features to progenitor populations and resistance to BCR-ABL1 tyrosine kinase inhibitors. Comprehensive models of BC transformation have proved elusive because of the rarity and genetic heterogeneity of BC, but are important for developing biomarkers predicting BC progression and effective therapies. To better understand BC, we performed an integrated multiomics analysis of 74 CP and BC samples using whole-genome and exome sequencing, transcriptome and methylome profiling, and chromatin immunoprecipitation followed by high-throughput sequencing. Employing pathway-based analysis, we found the BC genome was significantly enriched for mutations affecting components of the polycomb repressive complex (PRC) pathway. While transcriptomically, BC progenitors were enriched and depleted for PRC1- and PRC2-related gene sets respectively. By integrating our data sets, we determined that BC progenitors undergo PRC-driven epigenetic reprogramming toward a convergent transcriptomic state. Specifically, PRC2 directs BC DNA hypermethylation, which in turn silences key genes involved in myeloid differentiation and tumor suppressor function via so-called epigenetic switching, whereas PRC1 represses an overlapping and distinct set of genes, including novel BC tumor suppressors. On the basis of these observations, we developed an integrated model of BC that facilitated the identification of combinatorial therapies capable of reversing BC reprogramming (decitabine+PRC1 inhibitors), novel PRC-silenced tumor suppressor genes (NR4A2), and gene expression signatures predictive of disease progression and drug resistance in CP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020004834

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Ko, T. K., Javed, A., Lee, K. L., Pathiraja, T. N., Liu, X., Malik, S., Soh, S. X., Heng, X. T., Takahashi, N., Tan, J. H. J., Bhatia, R., Khng, A. J., Chng, W.-J., Sia, Y. Y., Fruman, D. A., Ng, K. P., Chan, Z. E., Xie, K. J., Hoi, Q., Chan, C. X., Teo, A. S. M., Velazquez Camacho, O., Meah, W. Y., Khor, C. C., Ong, C. T. J., Soon, W. J. W., Tan, P., Ng, P. C., Chuah, C., Hillmer, A. M., & Ong, S. T.
Venue
Blood
Published
2020-06-25
Volume
135
Issue
26
Pages
2337-2353
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3011495969
Cited by
72
References
23
FWCI
6.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.